ORLADEYO gains approval in Peru for HAE prevention
Pint Pharma has announced the approval in Peru of Orladeyo (berotralstat) for use as an oral therapy to prevent hereditary angioedema (HAE) attacks. Orladeyo is a product of BioCryst Pharmaceuticals. Pint Pharma owns its registration, marketing and …